Noltrexin endoprosthesis synovial fluid sterile 2 ml syringe

Mechanism of action NOLTREXIN acts by restoring the volume and viscosity of synovial fluid in the joints affected by osteoarthritis. As a result, the pain syndrome is relieved and joint mobility improves. The peculiarity of the endoprosthesis is its longer action as compared to pharmaceuticals and materials.

Biodegradation of polyacrylamide gel occurs through macrophage resorption and non-cellular lysis. Subjected to very slow biodegradation for more than 6 months. It is excreted mainly through the kidneys and liver without tissue damage. Implant metabolites (using radioactive tags) are detected in the urine and liver. Due to the safety of the drug and the practical absence of a tissue reaction, the implant does not need to be removed. The position and orientation of the implant in the joint cavity is not determined radiologically. If necessary, the implant can be removed by puncture and lavage of the joint cavity.

Indications

Deterioration in the functional characteristics of joints, joint pain resulting from degenerative and traumatic changes in synovial joints affected by osteoarthritis (osteoarthritis).

Pharmacological effect

Mechanism of action NOLTREXIN acts by restoring the volume and viscosity of synovial fluid in joints affected by osteoarthritis. As a result, pain is relieved and joint mobility is improved. A special feature of the endoprosthesis is its longer-lasting effect compared to pharmaceuticals and materials.”

Biodegradation of polyacrylamide gel occurs through resorption by macrophages and non-cellular lysis. Subject to very slow biodegradation over a period of more than 6 months. It is excreted mainly through the kidneys and liver without damaging the tissue. Implant metabolites (using radioactive tracers) are detected in urine and liver. Due to the safety of the drug and the virtual absence of tissue reaction, removal of the implant is not required. In the joint cavity, the position and orientation of the implant cannot be determined by radiological methods. If such a need arises, the implant can be removed by puncture and rinsing the joint cavity.

Special instructions

The treatment procedure, similar to other intra-articular injections, carries a minimal risk of complications (inflammation, arthralgia, internal bleeding due to vascular injury).

Observe the usual precautions: insertion of the endoprosthesis is possible only in a clean dressing room or operating room by qualified medical personnel. Keep out of the reach of children!

Composition

Three-dimensional polyacrylamide,%: 4.00 ± 1.50; • water,%: 96.00 ± 1.50; • silver ions, %: 0.0001 – 0.0025.

Side Effects

After administration of NOLTREXIN, a burning sensation in the joint may occur. The average duration of pain is 12–24 hours, but not more than 3 days. The pain syndrome is relieved by taking analgesics or non-steroidal anti-inflammatory drugs (the course is prescribed individually by the attending physician) or goes away on its own.

Interaction

Possible simultaneous use with local anesthetics, Xefocam, Diprospan, Traumeel-S or Zeel-T. The effect in combination with other products or drugs has not been studied.

Recommendations for use

The endoprosthesis is injected into the knee joint in quantities from 2.5 ml to 10.0 ml, one to four injections of 2.5 ml each with an interval of one week. Recommended technique:

first injection 2.5 ml or 5.0 ml,
the second 5.0 ml or 2.5 ml, depending on the stage and at the discretion of the doctor.

Hip joint: two injections of 2.5 ml or one 5.0 ml. The recommended interval between injections is one week.

The administration method is calculated individually depending on the stage of osteoarthritis and at the discretion of the doctor.

Repeated injection into the knee joint with the patient in a sitting position creates the possibility of damaging the cartilaginous covering of the articular surfaces and menisci with a large-diameter needle.

To avoid overfilling the joint with dense, slowly resorbable material, it is recommended to stop the course if the clinical result is good!

It is advisable to repeat the courses once every 6–24 months. depending on clinical manifestations.

The repeated course of injections can be shortened according to indications.

The endoprosthesis is injected into other joints with 2.5 ml or less, depending on the size of the joint.

Manufacturer

Bionoltra SA, Switzerland